MedTrace Logo

Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy

NCT06284356 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2024-03-01

No results posted yet for this study

Summary

Morbid obesity emerges as a problem that causes serious complications and increased mortality rates. The most effective treatment for morbid obesity today is surgical treatment. The most preferred type of surgery in morbid obesity surgery in Turkey and around the world is Laparoscopic Sleeve Gastrectomy (LSG).

While postoperative complications are divided into early and late complications, complications that develop during surgery and in the postoperative period before discharge are defined as perioperative complications. Early surgical complications after LSG include complications such as staple line bleeding, leaks, pulmonary thromboembolism, and torsion of the remnant stomach. It is important to detect these complications, which can be controlled with early intervention in the perioperative period.

Monitoring blood parameters and monitoring inflammation are methods that are easily accessible and provide rapid evaluation. Platelet lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), which are used in the evaluation and detection of postoperative complications, have shed light on studies in this direction. Pan immune inflammation value (PIV) is calculated from blood parameters and has been used to evaluate prognosis and chemotherapy results in colorectal cancer.

In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG.

Conditions

  • Morbid Obesity
  • Laparoscopic Sleeve Gastrectomy
  • Post Operative Complicaiton

Interventions

PROCEDURE

Laparoscopic Sleeve Gastrectomy

Laparoscopic Sleeve Gastrectomy

Sponsors & Collaborators

  • Elazig Special Eastern Anatolian Hospital

    collaborator UNKNOWN

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06284356 on ClinicalTrials.gov